Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.98 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.82 |
| ▸ | CIT | O14578 | 1/20 | 0.82 |
| ▸ | GAK | O14976 | 1/20 | 0.82 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.82 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.82 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.82 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.82 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.82 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.82 |
| ▸ | STK17B | O94768 | 1/20 | 0.82 |
| ▸ | STK10 | O94804 | 1/20 | 0.82 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.82 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.82 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.82 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.82 |
| ▸ | ABL1 | P00519 | 1/20 | 0.82 |
| ▸ | LCK | P06239 | 1/20 | 0.82 |
| ▸ | LYN | P07948 | 1/20 | 0.82 |
| ▸ | RET | P07949 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29731422 | 1.00 | EGFR (0.98) | EGFRERBB2CITGAKEPHB6 | |
| SCHEMBL22962690 | 0.92 | EGFR (0.84) | EGFRERBB2CITGAKEPHB6 | |
| SCHEMBL12012 | 0.92 | EGFR (1.00) | EGFRERBB2CITGAKEPHB6 | |
| SCHEMBL17520338 | 0.92 | EGFR (1.00) | EGFRERBB2CITGAKEPHB6 | |
| SCHEMBL22338480 | 0.92 | EGFR (0.92) | EGFRERBB2CITGAKEPHB6 | |
| SCHEMBL11395 | 0.92 | EGFR (1.00) | EGFRERBB2CITGAKEPHB6 | |
| SCHEMBL22336591 | 0.90 | EGFR (0.86) | EGFRERBB2CITGAKEPHB6 | |
| Gefitinib SCHEMBL29351046 | 0.90 | EGFR (1.00) | EGFRERBB2CITGAKEPHB6 | |
| Gefitinib SCHEMBL29351336 | 0.90 | EGFR (1.00) | EGFRERBB2CITGAKEPHB6 | |
| Gefitinib SCHEMBL465143 | 0.90 | EGFR (1.00) | EGFRERBB2CITGAKEPHB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023093701-A1 | PLATINUM (II) COMPOUND HAVING TARGETING EFFECT AND DERIVATIVE THEREOF, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE | 东南大学 | 2023-06-01 | — | — | WO | disclosed |
| US-20230063768-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-03-02 | — | — | US | disclosed |
| US-20220313829-A1 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-10-06 | — | — | US | disclosed |
| US-20220193242-A1 | IMMUNOPHILIN-DEPENDENT INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-23 | — | — | US | disclosed |
| WO-2022086853-A1 | STAR POLYMER DRUG CONJUGATES | AVIDEA TECHNOLOGIES, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2020163598-A1 | IMMUNOPHILIN-DEPENDENT INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020163594-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-08-13 | — | — | WO | disclosed |
| US-20110008447-A1 | CARRIER COMPRISING NANODIAMOND | NATIONAL CHIAO TUNG UNIVERSITY (TW) | 2011-01-13 | — | — | US | disclosed |
| US-20110008447-A1 | CARRIER COMPRISING NANODIAMOND | NATIONAL CHIAO TUNG UNIVERSITY (TW) | 2011-01-13 | — | — | US | disclosed |
| US-20090203683-A1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, THEIR USE, AND PROCESSES FOR PREPARING THEM | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-08-13 | — | — | US | disclosed |
| US-20060063752-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-03-23 | — | — | US | disclosed |
| EP-1163227-B1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, AND PROCESSES FOR PREPARING THEM | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-09-28 | — | — | EP | disclosed |
| US-20020177601-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-11-28 | — | — | US | disclosed |
| EP-1163227-A1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, AND PROCESSES FOR PREPARING THEM | Boehringer Ingelheim Pharma KG (DE) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000055141-A1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, AND PROCESSES FOR PREPARING THEM | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110008447-A1 | CARRIER COMPRISING NANODIAMOND | NDUFA9, NDUFB4, NDUFA2 | EGFR 3886/4885ERBB2 2750/4885CIT 1940/4885 |
| US-20220193242-A1 | IMMUNOPHILIN-DEPENDENT INHIBITORS AND USES THEREOF | CD74, CD2BP2, SERPINB1 | EGFR 3898/4885ERBB2 3502/4885CIT 1289/4885 |
| US-20090203683-A1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, THEIR USE, AND PROCESSES FOR PREPARING THEM | REN, APC, PKD1 | EGFR 2063/4885ERBB2 3690/4885CIT 2977/4885 |
| US-20230063768-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | PMP22, MAG, FABP7 | EGFR 3726/4885ERBB2 3924/4885CIT 1821/4885 |
| US-20060063752-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | REN, APC, PKD1 | EGFR 2063/4885ERBB2 3690/4885CIT 2977/4885 |
| US-20220313829-A1 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885CIT 4245/4885 |
| US-20020177601-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | PKD1, REN, BDKRB1 | EGFR 1367/4885ERBB2 2817/4885CIT 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.